Accrued Research and Development Milestone Payments

No definition available.

Name:	gild_AccruedResearchAndDevelopmentMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months

+ References

No definition available.

+ Details

Name:	gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Adjustments of Budgeted Development Costs, Payments, Due Year Two

+ References

No definition available.

+ Details

Name:	gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueYearTwo
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cash Payments Made Related to Equity Investments

+ References

No definition available.

+ Details

Name:	gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	gild_CollaborativeArrangementTerm
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Method Investment, Option Exercise Fee

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOptionExerciseFee
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity Method Investment, Option Fee And Potential Future Milestone Payments

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity Securities, FV-NI, Additional Option Fee on Second Anniversary

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIAdditionalOptionFeeOnSecondAnniversary
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity Securities, FV-NI, Future Maximum Milestone Payments

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIFutureMaximumMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Equity Securities, FV-NI, Purchase Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity Securities, FV-NI, Restriction Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Initial consideration for acquisition of rights to market and distribute certain products in Japan

+ References

No definition available.

+ Details

Name:	gild_InitialConsiderationforAcquisitionofRightstoMarketandDistributeCertainProductsinJapan
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Investment Owned, Balance, Additional Payable

+ References

No definition available.

+ Details

Name:	gild_InvestmentOwnedBalanceAdditionalPayable
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Investment Owned, Balance, Additional Shares

+ References

No definition available.

+ Details

Name:	gild_InvestmentOwnedBalanceAdditionalShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Issuance Discount (Premium)

+ References

No definition available.

+ Details

Name:	gild_IssuanceDiscountPremium
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Issuance discount

+ References

No definition available.

+ Details

Name:	gild_Issuancediscount
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement

+ References

No definition available.

+ Details

Name:	gild_MaximumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement

+ References

No definition available.

+ Details

Name:	gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Agreements

+ References

No definition available.

+ Details

Name:	gild_NumberOfAgreements
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Programs

+ References

No definition available.

+ Details

Name:	gild_NumberOfPrograms
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of Studies

+ References

No definition available.

+ Details

Name:	gild_NumberOfStudies
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payment for Adjustments of Budgeted Development Costs

+ References

No definition available.

+ Details

Name:	gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

payment for license, option rights and equity investments upon closing of collaboration agreement

+ References

No definition available.

+ Details

Name:	gild_PaymentforLicenseOptionRightsandEquityInvestmentsUponClosing
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments for Direct Transactional Expense

+ References

No definition available.

+ Details

Name:	gild_PaymentsForDirectTransactionalExpense
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments for Research and Development Milestones

+ References

No definition available.

+ Details

Name:	gild_PaymentsForResearchAndDevelopmentMilestones
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Clinical, Regulatory and Commercial Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialClinicalRegulatoryAndCommercialMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential Development and Regulatory Milestones

+ References

No definition available.

+ Details

Name:	gild_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Future Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Future Sales-based Milestone

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureSalesbasedMilestone
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential Future Tiered Royalty Payment High-end

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureTieredRoyaltyPaymentHighend
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Potential Future Tiered Royalty Payment Low-end

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureTieredRoyaltyPaymentLowend
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Potential Milestone Payment Upon Marketing Approval GLPG-1690

+ References

No definition available.

+ Details

Name:	gild_PotentialMilestonePaymentUponMarketingApprovalGLPG1690
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Option Exercise Fee Per Program

+ References

No definition available.

+ Details

Name:	gild_PotentialOptionExerciseFeePerProgram
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Payment for Adjustments of Budgeted Development Costs

+ References

No definition available.

+ Details

Name:	gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential Sales Based Tiered Royalties High-end, Percentage

+ References

No definition available.

+ Details

Name:	gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Potential Sales Based Tiered Royalty, Low-end, Percentage

+ References

No definition available.

+ Details

Name:	gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Purchase Price of Goods Less Specified Amount, Maximum Percentage

+ References

No definition available.

+ Details

Name:	gild_PurchasePriceofGoodsLessSpecifiedAmountMaximumPercentage
Namespace Prefix:	gild_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Research and Development Future Maximum Payments

+ References

No definition available.

+ Details

Name:	gild_ResearchAndDevelopmentFutureMaximumPayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Standstill Restricting Term

+ References

No definition available.

+ Details

Name:	gild_StandstillRestrictingTerm
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Total Upfront Payments Made

+ References

No definition available.

+ Details

Name:	gild_TotalUpfrontPaymentsMade
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Up-front Collaboration and Licensing Expenses Related to Other Collaboration Arrangements That Are Not Individually Significant

+ References

No definition available.

+ Details

Name:	gild_UpfrontCollaborationandLicensingExpensesRelatedtoOtherCollaborationArrangementsThatAreNotIndividuallySignificant
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Equity securities categorized neither as held-to-maturity nor trading which are intended be sold more than one year from the balance sheet date or operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	us-gaap_AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Fair value portion of investments accounted under the equity method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567

+ Details

Name:	us-gaap_EquityMethodInvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740

+ Details

Name:	us-gaap_EquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Portion of equity (net assets) in a variable interest entity (VIE) not attributable, directly or indirectly, to the parent entity. That is, this is the portion of equity in a VIE that is attributable to the noncontrolling interest (previously referred to as minority interest).

+ References

No definition available.

+ Details

Name:	us-gaap_NoncontrollingInterestInVariableInterestEntity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow from amounts paid for the rights to manage the property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireManagementContractRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedArcusCommonStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=gild_TangoTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=gild_JounceTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GadetaBVCollaborationArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_BristolMyersSquibbCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_FilgotinibLicenseAndCollaborationAgreementWithGalapagosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementIn2019Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GalapagosCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborations and Other Arrangements (Details) € / shares in Units, € in Millions, shares in Millions, $ in Millions				1 Months Ended						3 Months Ended			12 Months Ended			13 Months Ended
	Aug. 25, 2020 USD ($)	Aug. 17, 2020 USD ($) program	Jul. 13, 2020 USD ($) shares	Feb. 25, 2021 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2021 EUR (€)	Oct. 31, 2020 USD ($)	Aug. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2020 USD ($) study	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2020 USD ($) study	Dec. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) shares	Feb. 08, 2021 USD ($) shares	Dec. 31, 2020 EUR (€) study	Oct. 31, 2020 € / shares	Aug. 27, 2020	Jul. 17, 2020 agreement	Jul. 13, 2020 € / shares	Jun. 19, 2020 agreement	May 29, 2020 USD ($) shares	Aug. 31, 2019 € / shares	Jul. 31, 2018 USD ($)	Jan. 19, 2016 USD ($) shares	Jan. 19, 2016 € / shares	Dec. 31, 2014
Collaborative Arrangements
Acquired in-process research and development expenses													$ 5,856	$ 4,251	$ 0
Unrealized loss on investment of equity securities													1,700
Prepaid and other current assets										$ 2,013			2,013	1,440		$ 1,440
Cost of goods sold													4,572	4,675	4,853
Amended arcus common stock purchase agreement \| Arcus \| Subsequent event
Collaborative Arrangements
Ownership percentage by noncontrolling owners																	19.50%
Janssen pharmaceuticals
Collaborative Arrangements
Purchase price of goods less specified amount, maximum percentage																													30.00%
Cost of goods sold													570	574	608
Tango collaboration and stock purchase agreement \| Tango
Collaborative Arrangements
Ownership percentage by noncontrolling owners																				7.00%
Jounce license and stock purchase agreement \| Jounce
Collaborative Arrangements
Ownership percentage by noncontrolling owners							14.00%
Japan tobacco
Collaborative Arrangements
Prepaid and other current assets									$ 9						9
Finite-lived intangible assets acquired									$ 550
Amortization useful life									9 years
Royalty expense													291	358	452
Cash paid																559
Payments to acquire management contract rights									$ 194					365
Gadeta collaboration arrangement
Collaborative Arrangements
Noncontrolling interest in variable interest entity										82			82													$ 82
BMS collaborative arrangement
Collaborative Arrangements
Cost of goods sold													19	58	198
Other collaboration arrangements
Collaborative Arrangements
Cash payments made related to equity investments													72	118	156
Upfront collaboration expenses													129	331	$ 278
Arcus
Collaborative Arrangements
Shares of common stock acquired \| shares																								2.2
Collaboration and stock purchase agreement																								$ 61
Arcus \| Arcus collaboration agreement and stock purchase agreements
Collaborative Arrangements
Payments to acquire in process research and development			$ 175
Collaboration and stock purchase agreement			$ 200
Additional shares acquired (in shares) \| shares			6.0
Total upfront payments made			$ 391
Equity investment			135
Share price \| € / shares																						€ 22.67
Acquired in-process research and development expenses			256
Issuance discount (premium)			(65)
Direct transactional costs			16
Arcus \| Amended arcus common stock purchase agreement \| Subsequent event
Collaborative Arrangements
Shares of common stock acquired \| shares																	13.8
Collaboration and stock purchase agreement																	$ 220
Additional shares acquired (in shares) \| shares																	5.7
Arcus \| Arcus collaboration agreement
Collaborative Arrangements
Acquired in-process research and development expenses													100
Additional option fee on second anniversary			100
Additional option fee on fourth, sixth, and eighth anniversaries			100
Future milestone payments			$ 1,200
Collaborative Arrangement, Term			10 years
Arcus \| Arcus stock purchase agreement
Collaborative Arrangements
Purchase period			5 years
Maximum percentage of outstanding stock allowed to be purchased			35.00%
Restriction period			3 years
Pionyr
Collaborative Arrangements
Number of agreements \| agreement																							2
Ownership percentage																							49.90%
Pionyr \| Pionyr merger and option agreements
Collaborative Arrangements
Acquired in-process research and development expenses													215
Payments to acquire equity method investments			$ 269
Additional payable			6
Estimated fair value			70
Option exercise fee			315
Maximum potential future milestone payments			1,200
Pionyr \| Research and development service agreement
Collaborative Arrangements
Acquired in-process research and development expenses													80
Research and development future maximum payments			$ 115
Accrued research and development milestone payments										$ 70			$ 70
Number of studies \| study										2			2					2
Pionyr \| Research and development service agreement \| Subsequent event
Collaborative Arrangements
Cash payments made for research and development milestones				$ 70
Tizona
Collaborative Arrangements
Number of agreements \| agreement																					2
Ownership percentage																					49.90%
Tizona \| Tizona merger and option agreements
Collaborative Arrangements
Acquired in-process research and development expenses													$ 272
Payments to acquire equity method investments	$ 302
Estimated fair value	41
Option fee and potential future milestone payments	$ 1,300
Tizona \| Development agreement
Collaborative Arrangements
Acquired in-process research and development expenses													115
Tango \| Tango collaboration and stock purchase agreement
Collaborative Arrangements
Payments to acquire in process research and development		$ 125
Acquired in-process research and development expenses		125
Cash payments made related to equity investments		$ 20
Number of programs \| program		15
Collaborative Arrangement, Term		7 years
Opt-in, extension and milestone payments		$ 410
Jounce \| Jounce license and stock purchase agreement
Collaborative Arrangements
Total upfront payments made							$ 120
Share price \| € / shares																			€ 10.06
Acquired in-process research and development expenses													$ 64
Cash payments made related to equity investments							56
Future potential clinical, regulatory and commercial milestone payments							$ 685
Galapagos \| Filgotinib agreement
Collaborative Arrangements
Shares of common stock acquired \| shares																											6.8
Equity investment																											$ 357
Share price \| € / shares																												€ 58
Galapagos \| 2019 agreement
Collaborative Arrangements
Potential development and regulatory milestone-based payments														640		640
Potential future sales-based milestone payments														$ 600		$ 600
Potential future tiered royalty payment low-end														20.00%		20.00%
Potential future tiered royalty payment high-end														30.00%		30.00%
Galapagos \| Amended 2019 agreement
Collaborative Arrangements
Payment of tiered royalties, low-end percentage										8.00%			8.00%					8.00%
Payment of tiered royalties, high-end percentage										15.00%			15.00%					15.00%
Potential payment for adjustments of budgeted development costs										$ 190			$ 190					€ 160
Additional payment for adjustments of budgeted development costs in 2021										89			89					75
Payment for adjustments of budgeted development costs in 2022										60			60					€ 50
Galapagos \| Amended 2019 agreement \| Subsequent event
Collaborative Arrangements
Payment for adjustments of budgeted development costs					$ 42	€ 35
Galapagos \| Galapagos subscription agreement
Collaborative Arrangements
Shares of common stock acquired \| shares								6.8						16.7		16.7
Additional shares acquired (in shares) \| shares														2.6		2.6
Share price \| € / shares																									€ 140.59
Equity investments balancce								$ 1,130		1,650			1,650	$ 3,480		$ 3,480
Acquired in-process research and development expenses												$ 3,920		$ 3,920
Unrealized loss on investment of equity securities										628	$ 983		1,830
Ownership percentage														25.80%		25.80%
Prepaid and other current assets										$ 351			$ 351
Estimated fair value														$ 586		$ 586
Standstill restricting term								10 years
Maximum ownership percentage								29.90%
Minimum ownership percentage								20.10%
Payment for license and option rights								$ 5,050
Issuance discount								63
Galapagos \| Galapagos collaboration agreement
Collaborative Arrangements
Potential milestone payment upon marketing approval GLPG-1690								325
Potential option exercise fee								$ 150
Payment of tiered royalties, low-end percentage								20.00%
Payment of tiered royalties, high-end percentage								24.00%